Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 32 |
| Active Pipeline (Recruiting Now) | 24 (15) |
| Completed vs Stopped Early | 7 / 1 (3.1%) |
| Median Closed Actual Enrollment | 103 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong | 3 |
| Xiangya Hospital of Central South University | Changsha, Hunan | 2 |
| Peking University People's Hospital | Beijing, Beijing Municipality | 2 |
Explore interactive annual charts and M&A subsidiary rollups in the Guangdong Hengrui Pharmaceutical Co Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.